TaiMed Biologics Inc. (4147.TWO)
- Previous Close
81.80 - Open
82.80 - Bid --
- Ask --
- Day's Range
82.50 - 83.60 - 52 Week Range
76.30 - 135.00 - Volume
951,160 - Avg. Volume
2,431,957 - Market Cap (intraday)
22.604B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.76 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
88.00
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
www.taimedbiologics.comRelated News
Performance Overview: 4147.TWO
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4147.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4147.TWO
Valuation Measures
Market Cap
22.60B
Enterprise Value
22.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
43.19
Price/Book (mrq)
8.81
Enterprise Value/Revenue
46.17
Enterprise Value/EBITDA
-922.63
Financial Highlights
Profitability and Income Statement
Profit Margin
-39.61%
Return on Assets (ttm)
-2.60%
Return on Equity (ttm)
-7.38%
Revenue (ttm)
491.78M
Net Income Avi to Common (ttm)
-194.81M
Diluted EPS (ttm)
-0.76
Balance Sheet and Cash Flow
Total Cash (mrq)
646.5M
Total Debt/Equity (mrq)
29.26%
Levered Free Cash Flow (ttm)
82.39M
Research Analysis: 4147.TWO
Company Insights: 4147.TWO
4147.TWO does not have Company Insights